CDKN1A and hepatocellular carcinoma: PRMT1 has been found to be clearly associated with poor prognosis in HCC patient cohorts, which is supported by our findings as well as a recent RNA-seq analysis [57], showing conformance to the latest findings on the potential promotion of PRMT1 in HCC formation by means of CDKN1A downregulation, STAT3 activation [29], and immune checkpoint PD-L1 gene overexpression [58].